Hetero seeks emergency use approval for Molnupiravir, says helps in early recovery of mild COVID-19 patients - Hi friends, I hope you are all in good healthUPDATETIMES, In the article you are reading this time with the title Hetero seeks emergency use approval for Molnupiravir, says helps in early recovery of mild COVID-19 patients, We have prepared this article well for you to read and take information in it. hopefully the contents of the post Artikel IFTTT, Artikel Press Trust of India ( ), Artikel YourStory RSS Feed, what we write you can understand. ok, happy reading.

Title : Hetero seeks emergency use approval for Molnupiravir, says helps in early recovery of mild COVID-19 patients
link : Hetero seeks emergency use approval for Molnupiravir, says helps in early recovery of mild COVID-19 patients

Hetero seeks emergency use approval for Molnupiravir, says helps in early recovery of mild COVID-19 patients

The use of Molnupiravir, an experimental oral drug having antiviral properties, has resulted in early recovery of COVID patients with mild symptoms when compared to standard treatment during Phase-III clinical trials, Hetero said on Friday, citing interim data.

The Hyderabad-based drugmaker also said it has approached the Drug Controller General of India (DCGI), seeking Emergency Use Authorisation (EUA) for Molnupiravir use in India.

Hetero had commenced a Phase-III, comparative, randomised, multicenter clinical trial on mild COVID-19 patients.

Representational Image

ALSO READ

Crypto exchange CoinSwitch Kuber to double team size in 6 months

These clinical trials were aimed at evaluating the efficacy and safety of Molnupiravir and standard of care (test arm) versus standard of care alone (control arm) in mild COVID-19 patients with a positive SARS CoV-2 RT PCR test and randomised within five days of onset of symptoms.

In April 2021, Hetero had entered into a non-exclusive licensing agreement with MSD to manufacture and supply Molnupiravir in India and over 100 low and middle-income countries (LMICs).

There were fewer hospital admissions in the Molnupiravir group compared to the standard of care alone over 14 days of observation, the interim results said.

"Phase III trial demonstrates statistically significant fewer hospital admissions, faster time to clinical improvement, and early negative SARS CoV-2 RT PCR with Molnupiravir treatment in mild COVID-19 patients compared to standard of care alone," Hetero said.

There was no mortality in either group, and all adverse events were non-serious, mild in severity, and none led to drug discontinuation, the drugmaker said.

The most common adverse events reported were nausea, diarrhoea, and headache, which were resolved completely, according to Hetero, which is also undertaking a separate Molnupiravir study on moderate COVID-19 patients approved by Central Drugs Standard Control Organisation, the company added.

---

Edited by Suman Singh

Link : https://yourstory.com/2021/07/hetero-emergency-use-molnupiravir-drug-recovery-covid-patients
Author :- Press Trust of India ( )
July 09, 2021 at 08:33PM
YourStory

That's the article Hetero seeks emergency use approval for Molnupiravir, says helps in early recovery of mild COVID-19 patients

That's it for the article Hetero seeks emergency use approval for Molnupiravir, says helps in early recovery of mild COVID-19 patients this time, hopefully can be useful for all of you. okay, see you in another article post.

You are now reading the article Hetero seeks emergency use approval for Molnupiravir, says helps in early recovery of mild COVID-19 patients with link address https://updateboynew.blogspot.com/2021/07/hetero-seeks-emergency-use-approval-for.html